Pharmacokinetic parameters as a potential predictor of response to pharmacotherapy in benign prostatic hyperplasia: a preclinical trial using dynamic contrast-enhanced MRI

Magnetic Resonance Imaging

Volumn 24, Issue 6, 2006, Pages 721-725

  Jia, Guang ^a   Heverhagen, Johannes T ^a   Henry, Hannes ^a   Polzer, Hans ^a   Baudendistel, Klaus T ^a   von Tengg Kobligk, Hendrik ^a   Levine, Andrea L ^a   Rosol, Thomas J ^a   Knopp, Michael V ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Animal model; Benign prostatic hyperplasia; DCE MRI; Finasteride; Pharmacokinetics

Indexed keywords

CONTRAST MEDIUM; FINASTERIDE; GADOLINIUM; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; FOLLOW UP; IMAGE ANALYSIS; MALE; MEDICAL ASSESSMENT; MOLECULAR DYNAMICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN SIZE; PREDICTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZATION; SIGNAL PROCESSING;

ANIMALS; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; DOGS; ENZYME INHIBITORS; FINASTERIDE; HETEROCYCLIC COMPOUNDS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MICROCIRCULATION; ORGANOMETALLIC COMPOUNDS; PROSPECTIVE STUDIES; PROSTATE; PROSTATIC HYPERPLASIA; RANDOM ALLOCATION; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

ANIMALIA;

EID: 33745652047     PISSN: 0730725X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mri.2005.12.029     Document Type: Article

References (20)

1. Schuster G.A., and Schuster T.G. The relative amount of epithelium, muscle, connective tissue and lumen in prostatic hyperplasia as a function of the mass of tissue resected. J Urol 161 (1999) 1168-1173
2. Boyle P., Gould A.L., and Roehrborn C.G. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 48 (1996) 398-405
3. Bozec A., Ruffion A., Decaussin M., Andre J., Devonec M., Benahmed M., et al. Activation of caspases-3, -6, and -9 during finasteride treatment of benign prostatic hyperplasia. J Clin Endocrinol Metab 90 (2005) 17-25
4. Andriole G., Bruchovsky N., Chung L.W., Matsumoto A.M., Rittmaster R., Roehrborn C., et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 172 (2004) 1399-1403
5. Naslund M.J., Carlson A.M., and Williams M.J. A cost comparison of medical management and transurethral needle ablation for treatment of benign prostatic hyperplasia during a 5-year period. J Urol 173 (2005) 2090-2093
6. Gupta A., Aragaki C., Gotoh M., Masumori N., Ohshima S., Tsukamoto T., et al. Relationship between prostate specific antigen and indexes of prostate volume in Japanese men. J Urol 173 (2005) 503-506
7. Knopp M.V., von Tengg-Kobligk H., and Choyke P.L. Functional magnetic resonance imaging in oncology for diagnosis and therapy monitoring. Mol Cancer Ther 2 (2003) 419-426
8. Yankeelov T.E., Luci J.J., Lepage M., Li R., Debusk L., Lin P.C., et al. Quantitative pharmacokinetic analysis of DCE-MRI data without an arterial input function: a reference region model. Magn Reson Imaging 23 (2005) 519-529
9. Checkley D., Tessier J.J., Wedge S.R., Dukes M., Kendrew J., Curry B., et al. Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts. Magn Reson Imaging 21 (2003) 475-482
10. Pradel C., Siauve N., Bruneteau G., Clement O., de Bazelaire C., Frouin F., et al. Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: an in vivo assessment using dynamic MR imaging and macromolecular contrast media. Magn Reson Imaging 21 (2003) 845-851
11. Heverhagen J.T., von Tengg-Kobligk H., Baudendistel K.T., Jia G., Polzer H., Henry H., et al. Benign prostate hyperplasia: evaluation of treatment response with DCE MRI. MAGMA 17 (2004) 5-11
12. Jia G., Baudendistel K.T., von Tengg-Kobligk H., Heverhagen J.T., Polzer H., Henry H., et al. Assessing prostate volume by magnetic resonance imaging: a comparison of different measurement approaches for organ volume analysis. Invest Radiol 40 (2005) 243-248
13. Engelbrecht M.R., Huisman H.J., Laheij R.J., Jager G.J., van Leenders G.J., Hulsbergen-Van De Kaa C.A., et al. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 229 (2003) 248-254
14. 1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10 (1999) 223-232
15. Marks L.S., Partin A.W., Dorey F.J., Gormley G.J., Epstein J.I., Garris J.B., et al. Long-term effects of finasteride on prostate tissue composition. Urology 53 (1999) 574-580
16. Roehrborn C.G. The potential of serum prostate-specific antigen as a predictor of clinical response in patients with lower urinary tract symptoms and benign prostatic hyperplasia. BJU Int 93 Suppl 1 (2004) 21-26
17. Roehrborn C.G., Boyle P., Bergner D., Gray T., Gittelman M., Shown T., et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology 54 (1999) 662-669
18. Watanabe H. New concept of BPH: PCAR theory. Prostate 37 (1998) 116-125
19. Shibata Y., Fukabori Y., Ito K., Suzuki K., and Yamanaka H. Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride. J Urol 165 (2001) 289-293
20. Stolzenburg J.U., Schwalenberg T., Do M., Dorschner W., Salomon F.V., Jurina K., et al. Is the male dog comparable to human? A histological study of the muscle systems of the lower urinary tract. Anat Histol Embryol 31 (2002) 198-205